UroGen Pharma (URGN) Capital Expenditures (2017 - 2026)

UroGen Pharma (URGN) has reported Capital Expenditures for 10 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.

• Quarterly Capital Expenditures rose 1169.72% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 1079.64% YoY) and the FY2025 annual result came in at $4.6 million, up 415.53% from the prior year.
• Capital Expenditures rose to $2.3 million in Q1 2026 per URGN's latest filing, from -$1.6 million in the prior quarter.
• Over the last five years, Capital Expenditures for URGN reached as high as $6.0 million in Q3 2025 and fell as low as -$1.6 million in Q4 2025.
• A 5-year average of $354235.3 and a median of $169000.0 in 2022 frame the typical range for Capital Expenditures.
• The largest YoY upside for Capital Expenditures was 2066.34% in 2025 against a maximum downside of 829.68% in 2025.
• Year by year, Capital Expenditures stood at $269000.0 in 2022, then tumbled by 104.46% to -$12000.0 in 2023, then jumped by 1925.0% to $219000.0 in 2024, then sank by 829.68% to -$1.6 million in 2025, then soared by 245.93% to $2.3 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $2.3 million, -$1.6 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.